GRTX · Galera Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $15.0K | - | $130.0K | $84.0K | $93.0K | - | $305.0K | $1.43M | $1.49M | - |
| SG&A | $1.64M | - | $1.31M | $1.05M | $1.87M | - | $3.44M | $2.78M | $3.09M | - |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | - |
| D&A | - | - | - | - | $0 | - | - | - | $9.0K | - |
| Operating Income | ($1.66M) | - | ($1.44M) | ($1.14M) | ($1.96M) | - | ($5.91M) | ($4.21M) | ($4.58M) | - |
| Interest Expense | $0 | - | $0 | - | - | - | $0 | $0 | $0 | - |
| Income Tax | - | - | $0 | - | - | - | $0 | - | - | - |
| Net Income | ($1.61M) | - | ($1.39M) | ($1.07M) | ($1.59M) | - | ($5.58M) | ($4.06M) | ($4.38M) | - |
| EPS - Basic | ($0.01) | - | ($0.01) | $0.00 | ($0.01) | - | ($0.10) | ($0.07) | ($0.08) | - |
| EPS - Diluted | ($0.01) | - | ($0.01) | $0.00 | ($0.01) | - | ($0.10) | ($0.07) | ($0.08) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.50M | $6.38M | $4.47M | $5.23M | $6.69M | $8.29M | $8.46M | $10.75M | $13.47M | $18.26M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $699.0K | $265.0K | $434.0K | $202.0K | $744.0K | $1.27M | $296.0K | $812.0K | $1.05M | $1.38M |
| Current Assets | $6.06M | $7.09M | $4.90M | $5.95M | $7.56M | $10.00M | $8.90M | $11.96M | $15.19M | $21.63M |
| Total Assets | $6.16M | $7.20M | $5.00M | $6.05M | $7.66M | $10.10M | $8.90M | $16.38M | $19.65M | $26.14M |
| Current Liabilities | - | $645.0K | $598.0K | $347.0K | $975.0K | $1.67M | $914.0K | $2.13M | $2.01M | $4.96M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $1.14M | $645.0K | $151.65M | $151.40M | $152.02M | $153.77M | $151.96M | $154.41M | $154.34M | $157.33M |
| Stockholders' Equity | $728.0K | $3.97M | ($149.22M) | ($147.94M) | ($147.23M) | ($148.04M) | ($143.06M) | ($138.03M) | ($134.69M) | ($131.19M) |
| Retained Earnings | ($308.92M) | ($307.31M) | ($460.42M) | ($459.03M) | ($457.95M) | ($456.36M) | ($451.43M) | ($445.85M) | ($441.79M) | ($437.41M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($875.0K) | - | - | - | ($2.24M) | - | - | - | ($4.79M) | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - | $0 | - |
| Financing Cash Flow | $0 | - | - | - | $635.0K | - | - | - | $0 | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -26.1% | - | -27.7% | -17.8% | -20.8% | - | -62.7% | -24.8% | -22.3% | - |
| Return on equity | -220.6% | - | 0.9% | 0.7% | 1.1% | - | 3.9% | 2.9% | 3.3% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | - | 11.00 | 8.20 | 17.14 | 7.75 | 6.00 | 9.74 | 5.63 | 7.54 | 4.36 |
| Quick ratio | - | 11.00 | 8.20 | 17.14 | 7.75 | 6.00 | 9.74 | 5.63 | 7.54 | 4.36 |
| Cash ratio | - | 9.88 | 7.48 | 15.07 | 6.86 | 4.98 | 9.25 | 5.06 | 6.69 | 3.68 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 8.47 | 1.81 | -0.03 | -0.04 | -0.05 | -0.07 | -0.06 | -0.12 | -0.15 | -0.20 |
| Liabilities / Assets | 0.19 | 0.09 | 30.32 | 25.03 | 19.84 | 15.22 | 17.07 | 9.43 | 7.85 | 6.02 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 6.1x | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 15.7% | - | 75.7% | 73.0% | 57.1% | - | 55.9% | 75.0% | 67.0% | - |
| Net income growth (YoY) | -0.9% | - | 75.1% | 73.5% | 63.7% | - | 63.0% | 80.4% | 75.3% | - |
| EPS growth (YoY) | 0.0% | - | 90.0% | - | 87.5% | - | 69.7% | - | 84.0% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | -4.3% | -7.2% | -9.3% | -12.8% | -13.0% | -20.0% | -38.0% | -20.2% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Galera Therapeutics against the 5 most active filers in the same SIC group.